scout
News|Videos|April 17, 2025

Long-Term Safety and Efficacy of Selinexor Maintenance Treatment in Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer: Follow-up Subgroup Analysis of the ENGOT-EN5/GOG-3055/SIENDO Study

Dr. Debra Richardson presents a subgroup analysis of the SIENDO trial, showing that selinexor maintenance therapy significantly improves progression-free survival and delays subsequent treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer, with manageable safety and potential long-term benefit.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME